Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54 PLN | -0.37% | -1.64% | -6.09% |
May. 17 | Transcript : Ryvu Therapeutics S.A. - Special Call | |
Mar. 13 | Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 89.75M 22.81M | Sales 2025 * | 132M 33.62M | Capitalization | 1.25B 317M |
---|---|---|---|---|---|
Net income 2024 * | -161M -40.92M | Net income 2025 * | -140M -35.58M | EV / Sales 2024 * | 13.6 x |
Net cash position 2024 * | 26.93M 6.84M | Net Debt 2025 * | 65.62M 16.68M | EV / Sales 2025 * | 9.93 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | -0.37% | ||
1 week | -1.64% | ||
1 month | +9.09% | ||
3 months | -9.09% | ||
6 months | -8.32% | ||
Current year | -6.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 54 | -0.37% | 2,844 |
24-05-29 | 54.2 | +2.26% | 3,692 |
24-05-28 | 53 | -3.11% | 5,334 |
24-05-27 | 54.7 | -0.36% | 2,785 |
24-05-24 | 54.9 | +2.81% | 1,350 |
Delayed Quote Warsaw S.E., May 31, 2024 at 11:55 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.09% | 317M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- RVU Stock